NEU neuren pharmaceuticals limited

In a new development, renewal of the rare paediatric disease PRV...

  1. 6,527 Posts.
    lightbulb Created with Sketch. 25004
    In a new development, renewal of the rare paediatric disease PRV program has been tucked into a $1.2 tr funding package bill intended to keep the US government open after a January 30 deadline.

    The bill was passed by the House overnight and is due to be voted on by the Senate next week.

    It has been reported that the Trump administration has expressed support for the “Give Kids a Chance Act,” which seeks to extend the paediatric priority review voucher (PRV) program.

    The Department of Health and Human Services (HHS) is said to have addressed a letter to the Senate, urging lawmakers to pass the legislation.

    However, this has not been publicly confirmed by the HHS.

    Fingers crossed!

    https://www.researchamerica.org/marys-letters/an-important-step-forward/



    https://www.biospace.com/policy/rare-pediatric-disease-vouchers-pbm-reform-up-for-vote-in-house

    https://www.geneonline.com/trump-ad...nd-pediatric-priority-review-voucher-program/
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.